GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GTXI
Previous Symbol
CUSIP40052B10
Phone901-523-9700
Debt
Debt-to-Equity RatioN/A
Current Ratio4.32
Quick Ratio4.32
Price-To-Earnings
Trailing P/E Ratio-0.66
Forward P/E Ratio-0.70
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.78 per share
Price / Book0.65
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-30,430,000.00
Net MarginsN/A
Return on Equity-126.41%
Return on Assets-100.34%
Miscellaneous
Employees27
Outstanding Shares24,050,000
Market Cap$28.62 million
OptionableOptionable
GTX (NASDAQ:GTXI) Frequently Asked Questions
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
How were GTX's earnings last quarter?
GTx, Inc. (NASDAQ:GTXI) issued its earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.09. View GTX's Earnings History.
When is GTX's next earnings date?
What price target have analysts set for GTXI?
2 brokers have issued 12 month price targets for GTX's shares. Their predictions range from $17.00 to $45.00. On average, they anticipate GTX's share price to reach $31.00 in the next year. This suggests a possible upside of 2,572.4% from the stock's current price. View Analyst Price Targets for GTX.
What is the consensus analysts' recommendation for GTX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GTX.
Has GTX been receiving favorable news coverage?
Media stories about GTXI stock have trended negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. GTX earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future.
Who are some of GTX's key competitors?
Some companies that are related to GTX include DURECT (DRRX), Mersana Therapeutics (MRSN), Sol Gel Technologies (SLGL), Spero Therapeutics (SPRO), Sesen Bio (SESN), Cue Biopharma (CUE), Selecta Biosciences (SELB), Sierra Oncology (SRRA), BELLUS Health (BLUSF), Chembio Diagnostics (CEMI), Tiziana Life Sciences (TLSA), Iterum Therapeutics (ITRM), Eton Pharmaceuticals (ETON), PhaseBio Pharmaceuticals (PHAS) and Vernalis (VNLPY).
Who are GTX's key executives?
GTX's management team includes the folowing people:
- Dr. Robert James Wills Ph.D., Exec. Chairman (Age 64)
- Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 55)
- Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 69)
- Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 43)
- Dr. Diane C. Young, VP & Chief Medical Officer (Age 61)
Who are GTX's major shareholders?
GTX's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.00%), Vanguard Group Inc (1.94%), Vanguard Group Inc. (1.94%), Bridgeway Capital Management Inc. (1.14%), Candriam Luxembourg S.C.A. (1.09%) and Vivo Capital LLC (0.44%). Company insiders that own GTX stock include Diane C Young, Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover and Robert James Wills. View Institutional Ownership Trends for GTX.
Which institutional investors are buying GTX stock?
GTXI stock was acquired by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Candriam Luxembourg S.C.A., Vivo Capital LLC, BlackRock Inc., Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for GTX.
How do I buy shares of GTX?
Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GTX's stock price today?
One share of GTXI stock can currently be purchased for approximately $1.16.
How big of a company is GTX?
GTX has a market capitalization of $28.62 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.
What is GTX's official website?
How can I contact GTX?
GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]
MarketBeat Community Rating for GTX (NASDAQ GTXI)
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
